Moderate to Severe Chronic Plaque Psoriasis
Also known as: Moderate-to-severe Chronic Plaque Psoriasis
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB00051 | Adalimumab | A monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. |
| DB00095 | Efalizumab | A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB00051 | Adalimumab | Tumor necrosis factor | target |
| DB00095 | Efalizumab | Integrin alpha-L | target |
| DB00095 | Efalizumab | Integrin alpha-X | target |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB15154 | Vunakizumab | 1 / 2 | Completed | 1 |
| DB06410 | Doxercalciferol | 2 | Completed | 1 |
| DB16698 | Neihulizumab | 2 | Completed | 2 |
| DB00005 | Etanercept | 2 / 3 | Recruiting | 1 |
| DB14004 | Tildrakizumab | 2 / 3 | Recruiting | 1 |
| DB00051 | Adalimumab | 3 | Recruiting | 1 |
| DB12917 | Bimekizumab | 3 | Active Not Recruiting | 1 |
| DB12917 | Bimekizumab | 3 | Completed | 5 |
| DB09029 | Secukinumab | 3 | Completed | 1 |
| DB05679 | Ustekinumab | 3 | Active Not Recruiting | 1 |
| DB05679 | Ustekinumab | 3 | Completed | 2 |
| DB00092 | Alefacept | 4 | Completed | 1 |